top of page
  • Completed

NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Updated: Sep 25, 2022

NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

KRd

NCT01402284

Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and help the immune system kill cancer cells. Dexamethasone is a drug that helps stop inflammation. It is sometimes used to treat (alone or with other drugs) certain types of cancer, especially multiple myeloma. This combination of drugs has not been tested in people with multiple myeloma. Researchers want to see whether it is safe and effective for this group.

Objectives To test the effectiveness of combined carfilzomib, lenalidomide, and dexamethasone in treating multiple myeloma.


Sponsor

National Cancer Institute (NCI)


Collaborators

Celgene

Onyx Therapeutics, Inc.